Pfiz­er, Mer­ck KGaA throw in the tow­el on an­oth­er Baven­cio PhI­II as once bright hopes shriv­el fast

Pfiz­er and Mer­ck KGaA have hit the tri­fec­ta for PD-L1 fail­ure in ovar­i­an can­cer.

The two part­ners said late to­day that they are shut­ter­ing the Phase III JAVELIN Ovar­i­an PARP 100 study, their third straight fail in the ovar­i­an can­cer sec­tor in re­cent months. The de­ci­sion to close the tri­al, they added, was due to its ear­li­er set­backs as well as the ap­proval of As­traZeneca’s dom­i­nant PARP Lyn­parza in front­line cas­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER